Sign In
Buy ABT
$93.24
+2.73 (+3.02%)
At Close: Jun 25, 2026
Investors Heavily Search Abbott Laboratories (ABT): Here is What You Need to Know
10:01am, Wednesday, 23'rd Jul 2025
Zacks.com users have recently been watching Abbott (ABT) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
NVST or ABT: Which Is the Better Value Stock Right Now?
12:41pm, Tuesday, 22'nd Jul 2025
Investors looking for stocks in the Medical - Products sector might want to consider either Envista (NVST) or Abbott (ABT). But which of these two stocks presents investors with the better value oppor
Best Dividend Kings: July 2025
09:31am, Tuesday, 22'nd Jul 2025
14 Dividend Kings continue to outperform the S&P 500 in 2025. Dividend growth remains healthy, with one recent increase and a collective 2025 growth rate of 5.23%. Seventeen Dividend Kings currently a
Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield
12:34pm, Friday, 18'th Jul 2025
If you wonder whether Abbott Laboratories NYSE: ABT is a good buy in Q2 2025, the answer is yes. The company's management, portfolio, cash flow, capital return, and pipeline are why.
Are Medical Stocks Lagging Abbott Laboratories (ABT) This Year?
10:40am, Friday, 18'th Jul 2025
Here is how Abbott (ABT) and Astellas Pharma Inc. (ALPMY) have performed compared to their sector so far this year.
Down 9.0% in 4 Weeks, Here's Why Abbott (ABT) Looks Ripe for a Turnaround
10:36am, Friday, 18'th Jul 2025
Abbott (ABT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising ear
These Analysts Revise Their Forecasts On Abbott Following Q2 Results
09:03am, Friday, 18'th Jul 2025
Abbott Laboratories ABT reported better-than-expected sales and profits in the second quarter, but dialed back earnings and growth projections for the rest of the year.
Abbott Laboratories: What's Behind The Q2 Earnings Slump?
08:51am, Friday, 18'th Jul 2025
ABT, which had been outperforming the healthcare cohort from the S&P 500 and the S&P 500 itself all through this year, has slumped dramatically following yesterday's Q2 earnings. While Q2 sales beat e
Abbott CEO Robert Ford goes one-on-one with Jim Cramer
07:56pm, Thursday, 17'th Jul 2025
Abbott Chairman and CEO Robert Ford joins 'Mad Money' host Jim Cramer to talk quarterly results, lowering its full-year guidance, sale trends, and more.
Didn't see the recovery in China we were expecting, says Abbott Labs CEO on lowering guidance
07:55pm, Thursday, 17'th Jul 2025
Abbott Chairman and CEO Robert Ford joins 'Mad Money' host Jim Cramer to talk quarterly results, lowering its full-year guidance, sale trends, and more.
Abbott Laboratories CEO calls post-earnings stock decline 'a little bit of an overreaction'
07:12pm, Thursday, 17'th Jul 2025
Abbott Laboratories CEO Robert Ford unpacked his company's latest quarterly report in a Thursday interview with CNBC's Jim Cramer, saying that Wall Street's reaction to the results was too extreme. "I
Live: Abbott Labs (NYSE: ABT) Sinks 6% After Releasing Q2 Earnings
04:06pm, Thursday, 17'th Jul 2025
Live Updates Live Coverage Has Ended Abbott Still Down 8% 2:38 pm by Eric Bleeker We’re approaching the end of the trading day and Abbott remains down 8%. At the end of the day, the company narr
Abbott Laboratories (ABT) Q2 2025 Earnings Call Transcript
02:05pm, Thursday, 17'th Jul 2025
Abbott Laboratories (NYSE:ABT ) Q2 2025 Results Conference Call July 17, 2025 9:00 AM ET Company Participants Michael Comilla - Vice President of Investor Relations. Philip P. Boudreau - CFO & Executi
Abbott Reports 10.5% EPS Growth for Fiscal Q2
12:49pm, Thursday, 17'th Jul 2025
Abbott Laboratories (ABT -8.41%), a global healthcare company known for its medical devices, diagnostics, nutrition, and pharmaceuticals, reported fiscal 2025 earnings on Thursday, July 17, that narro
Abbott Stock Falls in Pre-Market Despite Q2 Earnings and Sales Beat
12:11pm, Thursday, 17'th Jul 2025
ABT beats on Q2 earnings and revenues with double-digit growth in Medical Devices, yet shares fall 5% pre-market.
